ArticleMolecular therapy oncolytics2021

Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma.

Hiroshi Kubo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.